Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Inflammatory Bowel Diseases | 19 | 2021 | 3209 | 2.06 | Why? |
| Crohn Disease | 12 | 2019 | 959 | 1.79 | Why? |
| Colitis, Ulcerative | 12 | 2019 | 1037 | 1.75 | Why? |
| Ustekinumab | 2 | 2018 | 216 | 1.24 | Why? |
| Gastrointestinal Agents | 6 | 2019 | 393 | 1.18 | Why? |
| Drug Substitution | 3 | 2019 | 385 | 0.76 | Why? |
| Spondylarthritis | 2 | 2018 | 174 | 0.75 | Why? |
| Gastroenterology | 3 | 2020 | 1352 | 0.74 | Why? |
| Sulfasalazine | 1 | 2018 | 87 | 0.73 | Why? |
| Biosimilar Pharmaceuticals | 2 | 2019 | 205 | 0.73 | Why? |
| Tumor Necrosis Factor-alpha | 10 | 2018 | 2483 | 0.67 | Why? |
| Hospitals, High-Volume | 1 | 2020 | 688 | 0.63 | Why? |
| Azathioprine | 1 | 2017 | 161 | 0.62 | Why? |
| Leukocyte L1 Antigen Complex | 1 | 2017 | 238 | 0.59 | Why? |
| Methotrexate | 2 | 2018 | 471 | 0.58 | Why? |
| Case Management | 1 | 2017 | 285 | 0.56 | Why? |
| Spondylitis, Ankylosing | 1 | 2017 | 231 | 0.56 | Why? |
| Biological Products | 2 | 2020 | 2331 | 0.54 | Why? |
| Steroids | 1 | 2018 | 904 | 0.48 | Why? |
| Infliximab | 5 | 2018 | 502 | 0.45 | Why? |
| Fellowships and Scholarships | 1 | 2019 | 931 | 0.42 | Why? |
| Patient Education as Topic | 1 | 2019 | 1476 | 0.37 | Why? |
| Remission Induction | 5 | 2018 | 950 | 0.36 | Why? |
| Gastrointestinal Diseases | 1 | 2020 | 2580 | 0.29 | Why? |
| Gastroenterologists | 2 | 2019 | 259 | 0.27 | Why? |
| Colonoscopy | 4 | 2018 | 738 | 0.27 | Why? |
| Delphi Technique | 2 | 2018 | 1257 | 0.25 | Why? |
| Disease Management | 2 | 2020 | 6841 | 0.22 | Why? |
| Mercaptopurine | 2 | 2017 | 68 | 0.21 | Why? |
| Antibodies, Monoclonal, Humanized | 3 | 2018 | 9335 | 0.21 | Why? |
| Travel | 1 | 2019 | 7220 | 0.21 | Why? |
| Ileitis | 1 | 2019 | 21 | 0.21 | Why? |
| Disease Progression | 2 | 2018 | 13580 | 0.20 | Why? |
| Intestinal Fistula | 1 | 2019 | 43 | 0.20 | Why? |
| Adalimumab | 3 | 2018 | 389 | 0.20 | Why? |
| San Marino | 1 | 2018 | 3 | 0.20 | Why? |
| Intestinal Mucosa | 2 | 2017 | 1046 | 0.19 | Why? |
| Rectal Fistula | 1 | 2018 | 38 | 0.18 | Why? |
| Professional Practice Gaps | 1 | 2018 | 41 | 0.18 | Why? |
| Colectomy | 2 | 2019 | 327 | 0.18 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2018 | 1454 | 0.17 | Why? |
| Patient Care Management | 2 | 2020 | 1514 | 0.17 | Why? |
| Pouchitis | 1 | 2017 | 20 | 0.17 | Why? |
| Italy | 14 | 2021 | 38444 | 0.17 | Why? |
| Mesalamine | 1 | 2017 | 89 | 0.17 | Why? |
| Proctocolectomy, Restorative | 1 | 2017 | 51 | 0.17 | Why? |
| Colitis | 1 | 2019 | 266 | 0.16 | Why? |
| Wound Healing | 2 | 2018 | 424 | 0.16 | Why? |
| Evidence-Based Medicine | 3 | 2018 | 3228 | 0.15 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.15 | Why? |
| Staff Development | 1 | 2018 | 222 | 0.14 | Why? |
| Quality Assurance, Health Care | 1 | 2020 | 596 | 0.14 | Why? |
| Patient Acuity | 2 | 2020 | 1755 | 0.14 | Why? |
| Clinical Trials, Phase II as Topic | 1 | 2018 | 801 | 0.14 | Why? |
| Professional Practice | 1 | 2018 | 322 | 0.14 | Why? |
| Data Interpretation, Statistical | 1 | 2019 | 657 | 0.14 | Why? |
| Infection Control | 2 | 2020 | 23131 | 0.14 | Why? |
| Administration, Intravenous | 1 | 2018 | 1115 | 0.13 | Why? |
| Appendectomy | 1 | 2019 | 585 | 0.13 | Why? |
| Chemical and Drug Induced Liver Injury | 1 | 2018 | 451 | 0.13 | Why? |
| Standard of Care | 1 | 2020 | 1297 | 0.13 | Why? |
| Hospital Units | 1 | 2020 | 1017 | 0.13 | Why? |
| Interdisciplinary Communication | 2 | 2018 | 1425 | 0.13 | Why? |
| Mentoring | 1 | 2019 | 432 | 0.12 | Why? |
| Humans | 38 | 2021 | 930598 | 0.12 | Why? |
| Recurrence | 2 | 2020 | 3675 | 0.12 | Why? |
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 1316 | 0.12 | Why? |
| Secondary Prevention | 1 | 2017 | 762 | 0.12 | Why? |
| Immunosuppressive Agents | 4 | 2020 | 6331 | 0.12 | Why? |
| Gastrointestinal Tract | 1 | 2020 | 1113 | 0.12 | Why? |
| Self Care | 1 | 2020 | 918 | 0.12 | Why? |
| Nurse's Role | 1 | 2019 | 614 | 0.11 | Why? |
| Practice Patterns, Physicians' | 2 | 2019 | 4927 | 0.10 | Why? |
| Immunization | 1 | 2019 | 2019 | 0.10 | Why? |
| Appendicitis | 1 | 2019 | 946 | 0.09 | Why? |
| Needs Assessment | 1 | 2018 | 2352 | 0.09 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.09 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.08 | Why? |
| Colorectal Neoplasms | 2 | 2019 | 1884 | 0.08 | Why? |
| Feces | 1 | 2020 | 4235 | 0.08 | Why? |
| Quality of Health Care | 1 | 2018 | 1948 | 0.08 | Why? |
| Consensus | 2 | 2018 | 6345 | 0.08 | Why? |
| Health Care Rationing | 1 | 2020 | 2558 | 0.07 | Why? |
| Risk Assessment | 2 | 2020 | 25439 | 0.07 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.07 | Why? |
| Pandemics | 7 | 2020 | 389249 | 0.07 | Why? |
| Body Mass Index | 1 | 2017 | 4306 | 0.07 | Why? |
| Autoimmune Diseases | 1 | 2018 | 1996 | 0.07 | Why? |
| MicroRNAs | 1 | 2017 | 1787 | 0.07 | Why? |
| Treatment Outcome | 7 | 2018 | 51732 | 0.07 | Why? |
| Liver | 1 | 2018 | 4007 | 0.07 | Why? |
| Severity of Illness Index | 4 | 2019 | 48226 | 0.06 | Why? |
| Adrenal Cortex Hormones | 2 | 2017 | 6537 | 0.06 | Why? |
| Adult | 11 | 2020 | 244371 | 0.06 | Why? |
| Female | 15 | 2020 | 380317 | 0.06 | Why? |
| Middle Aged | 11 | 2020 | 270681 | 0.05 | Why? |
| Antibodies, Monoclonal | 2 | 2018 | 8041 | 0.05 | Why? |
| Sex Factors | 1 | 2018 | 11014 | 0.05 | Why? |
| Communication | 1 | 2019 | 5206 | 0.05 | Why? |
| Age Factors | 2 | 2020 | 21039 | 0.05 | Why? |
| Mass Screening | 1 | 2020 | 8005 | 0.05 | Why? |
| Late Onset Disorders | 1 | 2019 | 30 | 0.05 | Why? |
| Male | 13 | 2020 | 367725 | 0.05 | Why? |
| Prospective Studies | 3 | 2020 | 43301 | 0.05 | Why? |
| Population Surveillance | 1 | 2017 | 4967 | 0.05 | Why? |
| Retrospective Studies | 7 | 2019 | 105322 | 0.05 | Why? |
| Prevalence | 2 | 2018 | 25773 | 0.05 | Why? |
| Constriction, Pathologic | 1 | 2019 | 212 | 0.05 | Why? |
| Hepatitis, Alcoholic | 1 | 2018 | 61 | 0.04 | Why? |
| Surveys and Questionnaires | 6 | 2021 | 43792 | 0.04 | Why? |
| Aminosalicylic Acid | 1 | 2017 | 8 | 0.04 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.04 | Why? |
| Polypharmacy | 1 | 2019 | 347 | 0.04 | Why? |
| Pathologists | 1 | 2018 | 168 | 0.04 | Why? |
| Incidence | 1 | 2018 | 25622 | 0.04 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 8811 | 0.04 | Why? |
| Genetic Markers | 1 | 2017 | 318 | 0.04 | Why? |
| Inflammation | 1 | 2018 | 13255 | 0.04 | Why? |
| Quality Improvement | 2 | 2018 | 2435 | 0.04 | Why? |
| Colonic Polyps | 1 | 2017 | 117 | 0.04 | Why? |
| Postoperative Period | 1 | 2017 | 651 | 0.04 | Why? |
| Drainage | 1 | 2018 | 414 | 0.04 | Why? |
| Uveitis | 1 | 2018 | 233 | 0.04 | Why? |
| Follow-Up Studies | 3 | 2018 | 17020 | 0.04 | Why? |
| Observer Variation | 1 | 2017 | 622 | 0.03 | Why? |
| Cyclosporine | 1 | 2017 | 449 | 0.03 | Why? |
| Patient Care Planning | 1 | 2018 | 582 | 0.03 | Why? |
| RNA, Viral | 1 | 2020 | 32276 | 0.03 | Why? |
| Infusions, Intravenous | 1 | 2017 | 1224 | 0.03 | Why? |
| Digestive System Surgical Procedures | 1 | 2019 | 677 | 0.03 | Why? |
| Quality Indicators, Health Care | 1 | 2017 | 580 | 0.03 | Why? |
| Animals | 2 | 2018 | 78931 | 0.03 | Why? |
| Terminology as Topic | 1 | 2017 | 546 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.03 | Why? |
| Withholding Treatment | 1 | 2017 | 798 | 0.03 | Why? |
| Antibodies | 1 | 2017 | 846 | 0.03 | Why? |
| Aftercare | 1 | 2020 | 1637 | 0.03 | Why? |
| Opportunistic Infections | 1 | 2017 | 602 | 0.03 | Why? |
| Cohort Studies | 3 | 2019 | 36005 | 0.03 | Why? |
| Young Adult | 5 | 2019 | 93724 | 0.03 | Why? |
| Attitude of Health Personnel | 2 | 2019 | 4741 | 0.03 | Why? |
| Organizational Innovation | 1 | 2020 | 2468 | 0.03 | Why? |
| Education, Medical, Continuing | 1 | 2017 | 638 | 0.03 | Why? |
| Critical Pathways | 1 | 2020 | 1587 | 0.03 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.02 | Why? |
| Combined Modality Therapy | 1 | 2018 | 3395 | 0.02 | Why? |
| Telemedicine | 1 | 2020 | 25032 | 0.02 | Why? |
| Non-alcoholic Fatty Liver Disease | 1 | 2018 | 907 | 0.02 | Why? |
| Quality of Life | 2 | 2020 | 9820 | 0.02 | Why? |
| Biopsy | 1 | 2017 | 2811 | 0.02 | Why? |
| Adolescent | 4 | 2019 | 86841 | 0.02 | Why? |
| Public Health Surveillance | 1 | 2020 | 3129 | 0.02 | Why? |
| Pregnancy Complications | 1 | 2017 | 1388 | 0.02 | Why? |
| Remote Consultation | 1 | 2020 | 2396 | 0.02 | Why? |
| Internationality | 1 | 2018 | 3297 | 0.02 | Why? |
| Early Detection of Cancer | 1 | 2017 | 1956 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.02 | Why? |
| Aged | 5 | 2019 | 215776 | 0.02 | Why? |
| Pregnancy | 2 | 2017 | 23879 | 0.02 | Why? |
| Gene Expression Regulation | 1 | 2017 | 4020 | 0.02 | Why? |
| Psoriasis | 1 | 2018 | 1739 | 0.02 | Why? |
| Glucocorticoids | 1 | 2019 | 4431 | 0.02 | Why? |
| Patient Care Team | 1 | 2018 | 3556 | 0.02 | Why? |
| Chronic Disease | 1 | 2018 | 5139 | 0.02 | Why? |
| Logistic Models | 1 | 2018 | 9089 | 0.02 | Why? |
| Patient Safety | 1 | 2018 | 4885 | 0.02 | Why? |
| Immunologic Factors | 1 | 2019 | 4206 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2017 | 7268 | 0.02 | Why? |
| Adaptation, Psychological | 1 | 2020 | 4996 | 0.01 | Why? |
| Referral and Consultation | 1 | 2018 | 4816 | 0.01 | Why? |
| Databases, Factual | 1 | 2017 | 6248 | 0.01 | Why? |
| Societies, Medical | 1 | 2017 | 6907 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2017 | 11304 | 0.01 | Why? |
| Child | 2 | 2019 | 70012 | 0.01 | Why? |
| Hospitalization | 2 | 2020 | 54280 | 0.01 | Why? |
| Physicians | 1 | 2018 | 4214 | 0.01 | Why? |
| Case-Control Studies | 1 | 2017 | 17671 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2017 | 10649 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2017 | 11367 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2018 | 88759 | 0.01 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.01 | Why? |
| Prognosis | 1 | 2018 | 32490 | 0.01 | Why? |
| Anti-Bacterial Agents | 1 | 2017 | 10083 | 0.01 | Why? |
| Time Factors | 1 | 2017 | 31397 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2018 | 25144 | 0.01 | Why? |
| Risk Factors | 1 | 2020 | 71621 | 0.01 | Why? |
Armuzzi's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(186)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(136)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_